WINTON GROUP Ltd lessened its stake in Colgate-Palmolive (NYSE:CL) by 7.0% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 443,365 shares of the company’s stock after selling 33,258 shares during the quarter. Colgate-Palmolive makes up approximately 1.0% of WINTON GROUP Ltd’s investment portfolio, making the stock its 14th largest position. WINTON GROUP Ltd’s holdings in Colgate-Palmolive were worth $32,299,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Jacobi Capital Management LLC raised its stake in Colgate-Palmolive by 125.5% in the 3rd quarter. Jacobi Capital Management LLC now owns 1,443 shares of the company’s stock valued at $104,000 after acquiring an additional 803 shares during the period. Krilogy Financial LLC raised its stake in Colgate-Palmolive by 23.0% in the 2nd quarter. Krilogy Financial LLC now owns 1,547 shares of the company’s stock valued at $115,000 after acquiring an additional 289 shares during the period. Hanson & Doremus Investment Management raised its stake in Colgate-Palmolive by 4.5% in the 2nd quarter. Hanson & Doremus Investment Management now owns 1,630 shares of the company’s stock valued at $121,000 after acquiring an additional 70 shares during the period. Captrust Financial Advisors bought a new stake in Colgate-Palmolive in the 2nd quarter valued at $122,000. Finally, AlphaMark Advisors LLC raised its stake in Colgate-Palmolive by 1.5% in the 2nd quarter. AlphaMark Advisors LLC now owns 1,698 shares of the company’s stock valued at $126,000 after acquiring an additional 25 shares during the period. 72.83% of the stock is owned by institutional investors.
Colgate-Palmolive (NYSE CL) opened at $74.55 on Friday. The company has a current ratio of 1.23, a quick ratio of 0.92 and a debt-to-equity ratio of 24.42. The firm has a market capitalization of $65,460.00, a price-to-earnings ratio of 28.78, a price-to-earnings-growth ratio of 3.21 and a beta of 0.81. Colgate-Palmolive has a 12-month low of $63.43 and a 12-month high of $77.27.
Colgate-Palmolive (NYSE:CL) last posted its quarterly earnings data on Friday, October 27th. The company reported $0.73 earnings per share for the quarter, hitting the consensus estimate of $0.73. Colgate-Palmolive had a return on equity of 2,782.56% and a net margin of 15.10%. The firm had revenue of $3.97 billion for the quarter, compared to analysts’ expectations of $3.94 billion. During the same quarter last year, the business earned $0.73 EPS. The company’s quarterly revenue was up 2.8% compared to the same quarter last year. sell-side analysts forecast that Colgate-Palmolive will post 2.88 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Thursday, February 15th. Investors of record on Tuesday, January 23rd will be given a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a dividend yield of 2.15%. Colgate-Palmolive’s payout ratio is currently 61.78%.
In related news, insider Jennifer Daniels sold 902 shares of the firm’s stock in a transaction on Tuesday, January 9th. The stock was sold at an average price of $75.82, for a total value of $68,389.64. Following the transaction, the insider now owns 37,788 shares in the company, valued at $2,865,086.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Stephen I. Sadove sold 20,780 shares of the firm’s stock in a transaction on Monday, November 6th. The stock was sold at an average price of $70.52, for a total value of $1,465,405.60. Following the completion of the transaction, the director now owns 36,268 shares in the company, valued at approximately $2,557,619.36. The disclosure for this sale can be found here. Insiders sold 181,950 shares of company stock worth $13,237,385 in the last 90 days. 1.02% of the stock is owned by company insiders.
CL has been the topic of a number of research analyst reports. Zacks Investment Research cut Colgate-Palmolive from a “buy” rating to a “hold” rating in a research note on Tuesday, September 26th. Jefferies Group restated a “hold” rating and issued a $79.00 price target on shares of Colgate-Palmolive in a research note on Thursday, September 28th. Morgan Stanley lowered their price objective on Colgate-Palmolive from $84.00 to $83.00 and set an “overweight” rating on the stock in a research report on Tuesday, October 31st. KeyCorp reiterated a “hold” rating on shares of Colgate-Palmolive in a research report on Monday, October 16th. Finally, Macquarie started coverage on Colgate-Palmolive in a research report on Thursday, September 14th. They set a “neutral” rating and a $76.00 price objective on the stock. Two analysts have rated the stock with a sell rating, thirteen have issued a hold rating and six have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $76.51.
Colgate-Palmolive Company Profile
Colgate-Palmolive Company (Colgate) is a consumer products company. The Company operates in two product segments: Oral, Personal and Home Care, and Pet Nutrition. The Oral, Personal and Home Care product segment is operated through five geographic segments, which include North America, Latin America, Europe, Asia Pacific and Africa/Eurasia.
Want to see what other hedge funds are holding CL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Colgate-Palmolive (NYSE:CL).
Receive News & Ratings for Colgate-Palmolive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Colgate-Palmolive and related companies with MarketBeat.com's FREE daily email newsletter.